Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb has reported that its Orencia drug, which is used to treat rheumatoid arthritis in adults, has demonstrated potential in treating juvenile idiopathic arthritis.
Subscribe to our email newsletter
Results from the company’s investigational study suggested that Orencia reduced flare-ups of the disease in children who were not helped by other anti-rheumatic drugs such as methotrexate or tumor necrosis factor antagonists.
The ongoing study is designed to assess the efficacy, safety and tolerability of Orencia in patients ranging from six years to 17 years old.